Endogenous Cushing’s Syndrome (CS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 

Endogenous Cushing's syndrome (CS) is an uncommon endocrine disorder characterized by an overproduction of cortisol stemming from either ACTH-dependent conditions, typically an ACTH-producing pituitary adenoma (known as Cushing's disease), or ACTH-independent causes, most commonly a benign adrenal adenoma. While the primary effects of endogenous Cushing's syndrome are evident in its phenotypic changes and metabolic consequences, it also significantly impacts other endocrine axes. Inappropriate cortisol secretion can disrupt the activity of the hypothalamus-pituitary-thyroid axis, resulting in clinical and biochemical features indicative of "central hypothyroidism." Medical treatment for Cushing's disease is primarily utilized as a secondary option following unsuccessful surgery or recurrence. It involves various pituitary-directed medications, adrenal steroidogenesis inhibitors, and a glucocorticoid receptor blocker, some of which have received approval from the US Food and Drug Administration (FDA). Notably, recent consensus guidelines from the Pituitary Society endorse osilodrostat, an oral 11β-hydroxylase inhibitor, as an effective FDA-approved medical therapy for Cushing's disease. Despite achieving remission, patients often contend with several persistent comorbidities that can significantly impact their quality of life. Hence, prompt and accurate diagnosis, followed by timely intervention, is imperative for mitigating the chronic complications associated with excessive glucocorticoid levels and enhancing patient well-being.

 

Thelansis’s “Endogenous Cushing’s Syndrome (CS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Endogenous Cushing’s Syndrome (CS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Endogenous Cushing’s Syndrome (CS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Endogenous Cushing’s Syndrome (CS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Endogenous Cushing’s Syndrome (CS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033